18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.

scientific article

18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2967/JNUMED.108.058396
P8608Fatcat IDrelease_u3rdgrrhwbbndnfadxnnr6wdbm
P698PubMed publication ID19289420
P5875ResearchGate publication ID24203810

P50authorMartin WalterQ42847024
P2093author name stringRebecca A Dumont
Michael W Yeh
Matthias R Benz
Vatche G Agopian
Martin S Auerbach
Johannes G Czernin
Farzin Imani
Chi Kien Lai
Firoozeh Imani
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectphaeochromocytomaQ536269
P304page(s)513-519
P577publication date2009-03-16
P1433published inThe Journal of Nuclear MedicineQ7743608
P1476title18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
P478volume50

Reverse relations

cites work (P2860)
Q3808241718F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type
Q64988101Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls.
Q35009855Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma
Q37482780Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma
Q58005428Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis
Q37987448Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis
Q36467722EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma
Q33744014Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas).
Q51510849Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
Q37986065Imaging with non-FDG PET tracers: outlook for current clinical applications
Q37962361Malignant pheochromocytomas and paragangliomas: a diagnostic challenge
Q37730951Molecular imaging of neuroendocrine tumors
Q33897851Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytoma syndrome
Q41839681Nuclear medicine imaging in the evaluation of endocrine hypertension
Q35972320Pheochromocytoma and paraganglioma: current functional and future molecular imaging
Q34410500Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment
Q34145968Pheochromocytoma in a Twelve-Year-Old Girl with SDHB-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome.
Q37618594Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapy.
Q34266352SDHB-Associated Paraganglioma in a Pediatric Patient and Literature Review on Hereditary Pheochromocytoma-Paraganglioma Syndromes.
Q38348673The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review